U.S. markets closed
  • S&P Futures

    3,440.00
    -11.75 (-0.34%)
     
  • Dow Futures

    28,109.00
    -80.00 (-0.28%)
     
  • Nasdaq Futures

    11,630.50
    -33.00 (-0.28%)
     
  • Russell 2000 Futures

    1,626.50
    -9.10 (-0.56%)
     
  • Crude Oil

    39.20
    -0.65 (-1.63%)
     
  • Gold

    1,899.40
    -5.80 (-0.30%)
     
  • Silver

    24.50
    -0.17 (-0.69%)
     
  • EUR/USD

    1.1851
    +0.0025 (+0.21%)
     
  • 10-Yr Bond

    0.8410
    -0.0070 (-0.83%)
     
  • Vix

    27.55
    -0.56 (-1.99%)
     
  • GBP/USD

    1.3052
    -0.0029 (-0.22%)
     
  • USD/JPY

    104.7190
    -0.1210 (-0.12%)
     
  • BTC-USD

    13,033.16
    +15.63 (+0.12%)
     
  • CMC Crypto 200

    260.05
    -1.40 (-0.54%)
     
  • FTSE 100

    5,860.28
    +74.63 (+1.29%)
     
  • Nikkei 225

    23,516.59
    +42.29 (+0.18%)
     

CooperCompanies Announces Release Date for Third Quarter 2020

The Cooper Companies, Inc.
·1 min read

SAN RAMON, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today announced it will release third quarter 2020 financial results on Thursday, September 3, 2020, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments.

The live dial-in number for the call is 855-643-4430 (U.S.) / 707-294-1332 (International). The participant passcode for the call is “Cooper”. A simultaneous webcast of the call will be available through the “Investor Relations” section of the CooperCompanies website at http://investor.coopercos.com and a transcript of the call will be archived on this site for a minimum of 12 months.

A recording of the call will be available beginning at 8:00 PM ET on September 3, 2020 through September 10, 2020. To hear this recording, dial 855-859-2056 (U.S.) / 404-537-3406 (International) and enter code 5588359.

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.

Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
ir@cooperco.com